Vetter looks ahead to further expansions to meet supply chain demand

Work in progress at Vetter´s site in Ravensburg.

Ongoing investments in the supply chain for complex injectable medications

We are announcing additional investments as part of our long-term dedication to customer partnerships. Our extensive 40+ years of experience in aseptic filling and packaging shows a consistent desire for sustainable growth and corporate development. We are planning with future-driven considerations to meet our long-lead goals for continued expansion and customer satisfaction.

We are investing 230 million euros in our new production building, which is currently under construction at our global corporate headquarters site in Ravensburg. We recently reached a significant milestone in the construction process, as the shell of the building is now complete, following the start of construction in November 2021. The building is 122m long, 44m wide and 32m tall and will feature several new commercial filling lines to effectively increase aseptic manufacturing capacity for our global customer base. We are planning to install the first cleanrooms by the end of 2024.

According to our Managing Director Thomas Otto, “Our new production building signifies our ongoing dedication to support the needs of our customers concerning their complex injectable drug products with regards to packaging systems, specific process requirements and batch sizes. This is just one of several investments we are currently undertaking to manage our sustainable growth.”

Further investments include the increase of our lab space for analytical services, the expansion of filling capacity through new commercial production lines at other sites in the EU, the expansion in cool storage and warehousing, as well as a new technical equipment warehouse. Added to this are the optimization of infrastructure at our global sites to further develop processes, the development of new compounding and preparation rooms, and as a result, the optimization of the handling incoming and outgoing products.

“In our industry, the needs of our customers and the patients they serve continue to evolve,” emphasizes Vetter Managing Director Peter Soelkner. “Our job as a leading CDMO is to act as a strong partner, take the proactive steps necessary to identify relevant industry trends, and thus, to meet the evolving demands of the market through offering adequate resources. Over the coming years, we will continue to make further investments to stay on track with this commitment that we have made as a service provider, from the early development phase to aseptic fill and finish through assembly and packaging services.”